You just read:

Analyses of Pooled Data from Three Phase III Trials of Pirfenidone (Esbriet[®▼]) Show a Favourable and Persistent Treatment Benefit on Disease Progression in Patients with Idiopathic Pulmonary Fibrosis up to 72 weeks

News provided by

InterMune

09 Sep, 2014, 11:20 BST